ad image

Company Info

AstraZeneca

AstraZeneca

Drug Discovery & Development

Overview

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas  oncology, cardiovascular and metabolic diseases and respiratory. The company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
AstraZeneca
Contributions
32 Contributions1 / 2
AstraZeneca
Clinical Data

New Fasenra® Data from the Meltemi Extension Trial Confirm Long-term Safety and Efficacy in Severe Eosinophilic Asthma for up to Five Years

AstraZeneca

PR-M06-21-004Jun 02, 2021
AstraZeneca
Drug Approval

Farxiga Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type-2 Diabetes

AstraZeneca

PR-M05-21-004-1000May 06, 2021
AstraZeneca

COVID-19 Long-Acting AntiBody (LAAB) Combination AZD7442 Rapidly Advances into Phase III Clinical Trials

AstraZeneca

PR-M10-20-07Oct 13, 2020
AstraZeneca
Breakthrough Therapy

Farxiga Granted Breakthrough Therapy Designation in U.S. for Chronic Kidney Disease

AstraZeneca

PR-M10-20-02Oct 02, 2020
AstraZeneca

AstraZeneca, Oxford SARS-CoV-2 Vaccine Trials Temporarily Paused

AstraZeneca

PR-M09-20-NI-11Sep 09, 2020
AstraZeneca
COVID-19

Biopharma Leaders Unite to Stand with Science

AstraZeneca

PR-M09-20-NI-11-1307Sep 08, 2020
AstraZeneca
Clinical Trials

AstraZeneca Initiates Phase I Clinical Trial Initiated for Monoclonal Antibody Combination for COVID-19

AstraZeneca

PR-M08-20-NI-38Aug 25, 2020
AstraZeneca
Flu Vaccine

AstraZeneca Ships FLUMIST QUADRIVALENT Vaccine in the U.S. for 2020-2021 Flu Season

AstraZeneca

PR-M08-20-NI-25Aug 14, 2020
AstraZeneca
COVID-19 Vaccine

AstraZeneca Signs COVID-19 Vaccine Deal with Chinese Company

AstraZeneca

PR-M08-20-NI-12Aug 07, 2020
AstraZeneca
Collaboration

AstraZeneca and Daiichi Sankyo Enter Collaboration to Develop and Commercialize New Antibody Drug Conjugate

AstraZeneca

PR-M07-20-NI-41Jul 27, 2020
AstraZeneca
Approval

AstraZeneca's Breztri Aerosphere Approved in the US for the Maintenance Treatment of COPD

AstraZeneca

PR-M07-20-NI-37Jul 24, 2020
AstraZeneca
Clinical Results

AstraZeneca's Drug Significantly Reduces the Rate of the Composite of Stroke and Death in Patients

AstraZeneca

PR-M07-20-NI-027Jul 16, 2020
AstraZeneca
Oncology

Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukemia in Two Trials

AstraZeneca

PR-M06-20-NI-019-1504Jun 12, 2020
AstraZeneca
Collaboration

AstraZeneca to Discover and Develop Novel Therapies Targeting RNA-Modifying Proteins in Oncology Collaboration with Accent Therapeutics

AstraZeneca

PR-M06-20-NI-005Jun 04, 2020
AstraZeneca
Oncology

AstraZeneca Collaborates with ArcherDX to Use Personalized Cancer Assays to Detect Minimal Residual Disease in Lung Cancer Trials

AstraZeneca

PR-M05-20-NI-044May 29, 2020
AstraZeneca
COVID-19 Vaccine

AstraZeneca Advances Response to COVID-19 After Receiving First Commitments for Oxford’s Potential New Vaccine

AstraZeneca

PR-M05-20-NI-033May 21, 2020
AstraZeneca
Licensing

AstraZeneca Completes Recovery of Global Rights to Brazikumab from Allergan

AstraZeneca

PR-M05-20-NI-019May 14, 2020
AstraZeneca
Drug Approval

Farxiga Approved in the US for the Treatment of Heart Failure in Patients

AstraZeneca

PR-M05-20-NI-015May 08, 2020
AstraZeneca
COVID-19 Vaccine

AstraZeneca and Oxford University Announce Landmark Agreement for COVID-19 Vaccine

AstraZeneca

PR-M04-20-NI-042Apr 30, 2020
AstraZeneca
Sustainability

AstraZeneca’s ‘Ambition Zero Carbon’ Strategy to Eliminate Emissions by 2025 and be Carbon Negative Across the Entire Value Chain by 2030

AstraZeneca

PR-M01-20-NI-035-1783Jan 23, 2020
1 / 2
0 Contributors1 / 0

No authors found

1 / 0